| Literature DB >> 26801060 |
Michael G Katz1, Anthony S Fargnoli1, Andrew P Kendle2, Roger J Hajjar3, Charles R Bridges4.
Abstract
The concept of gene therapy was introduced in the 1970s after the development of recombinant DNA technology. Despite the initial great expectations, this field experienced early setbacks. Recent years have seen a revival of clinical programs of gene therapy in different fields of medicine. There are many promising targets for genetic therapy as an adjunct to cardiac surgery. The first positive long-term results were published for adenoviral administration of vascular endothelial growth factor with coronary artery bypass grafting. In this review we analyze the past, present, and future of gene therapy in cardiac surgery. The articles discussed were collected through PubMed and from author experience. The clinical trials referenced were found through the Wiley clinical trial database (http://www.wiley.com/legacy/wileychi/genmed/clinical/) as well as the National Institutes of Health clinical trial database (Clinicaltrials.gov).Entities:
Mesh：
Substances：
Year: 2016 PMID： 26801060 PMCID： PMC4987708 DOI： 10.1016/j.athoracsur.2015.12.004
Source DB: PubMed Journal: Ann Thorac Surg ISSN： 0003-4975 Impact factor: 4.330